• Cy3 NHS ester (non-sulfonated): Practical Workflow

  2026-09-25

  Cy3 NHS ester (non-sulfonated) provides an orange fluorescent label for amino-containing proteins, peptides, and oligonucleotides when an organic co-solvent can be used. Because it is insoluble in water, it is a poor choice for aqueous-only labeling or delicate biomolecules that cannot tolerate DMSO or DMF.

• Valemetostat (DS-3201) in Lymphoma Research

  2026-09-24

  Valemetostat (DS-3201) gives lymphoma researchers a way to test how EZH1/EZH2-linked H3K27 trimethylation shapes tumor-cell behavior, with workflows that pair target engagement with functional readouts. This guide translates the clinical rationale into practical dose, timing, control, and troubleshooting choices for preclinical studies—not treatment advice.

• Cholesterol in LNP Research: Workflow & Troubleshooting

  2026-09-24

  Use Cholesterol as a controlled formulation variable to connect membrane biology with lipid nanoparticle experiments—without assuming it was the active ingredient in a specific therapy. This guide turns a bladder-cancer mRNA study into practical choices for formulation controls, cell assays, and troubleshooting.

• Cy3 NHS ester (non-sulfonated) Labeling Guide

  2026-09-23

  Cy3 NHS ester (non-sulfonated) provides an orange fluorescent label for biomolecules with accessible primary amines, including proteins, peptides, and appropriately modified oligonucleotides. Its water insolubility makes it a poor choice when a delicate protein cannot tolerate an organic co-solvent; consider a sulfonated NHS ester for those workflows.

• G007-LK: From Tankyrase Biology to Translation

  2026-09-23

  G007-LK connects tankyrase enzymology with Wnt/β-catenin and Hippo pathway biology, offering translational researchers a mechanistically resolved tool for APC-mutant colorectal cancer research, hepatocellular carcinoma models, and biomarker-driven experimental design.

• Leptin (116-130), amide, mouse Workflow

  2026-09-22

  Build reproducible metabolic and inflammatory assays with a defined leptin fragment designed for mechanistic research. This workflow emphasizes solvent control, short-term solution handling, dose-ranging, and cautious translation of SIRT6-AMPK-NLRP3 findings into leptin-focused experiments.

• Gastric Cancer Assembloids Reveal Stromal Drug Effects

  2026-09-22

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine matched tumor organoids with stromal cell subpopulations from the same tumor. The model reproduced tumor–stroma interactions, altered gene expression, and patient- and drug-specific response patterns, providing a more physiologically relevant platform for resistance studies and personalized treatment testing.

• Formononetin Protects Against Oxaliplatin Neurotoxicity

  2026-09-21

  The reference study identifies formononetin as a selective neuroprotective candidate that reduces oxaliplatin-induced oxidative stress and neuronal apoptosis through the Nrf2/HO-1 pathway. Its major translational contribution is showing that neuroprotection can be separated from broad antioxidant activity: formononetin preserved oxaliplatin and paclitaxel anticancer effects, whereas N-acetylcysteine weakened them.

• AIBP–LRP2 Signaling Restricts Collateral Circulation

  2026-09-21

  The reference study identifies an AIBP–LRP2–HDL–miR-223 pathway that suppresses CXCR4-positive, stemlike capillary endothelial cells during collateral vessel formation. Its findings support a two-phase model in which CXCR4 enables capillary expansion before arterial remodeling, offering a mechanistic framework for studying revascularization in peripheral artery disease.

• Afatinib in Gastric Cancer Assembloids

  2026-09-20

  Afatinib (BIBW 2992) provides a mechanistic probe for EGFR, HER2, and HER4 signaling in patient-derived gastric cancer assembloids. Learn how matched tumor–stroma models can reveal response changes that organoid-only assays may conceal.

• PKM2 inhibitor (compound 3k): Applied Workflows

  2026-09-19

  PKM2 inhibitor (compound 3k) provides a practical way to connect glycolytic control with cancer-cell viability and macrophage immunometabolism. This guide covers dose planning, ECAR/OCR validation, xenograft translation, and troubleshooting for selective PKM2-directed experiments.

• Cefodizime for AMR E. coli Research

  2026-09-18

  Cefodizime combines a defined penicillin-binding protein mechanism with broad in vitro activity, making it useful for antimicrobial susceptibility, resistance-surveillance, and host–pathogen assay design. This workflow-focused guide shows how to evaluate Cefodizime against urban rodent-derived Escherichia coli while separating direct bacterial killing from possible immunomodulatory effects.

• Rottlerin: PKC Inhibitor Workflow for S2 Cells

  2026-09-18

  Use Rottlerin as a pharmacological probe to test how PKC-dependent signaling contributes to Spiroplasma eriocheiris uptake, intracellular expansion, and host-cell injury. This workflow combines entry-focused sampling with viability, imaging, and apoptosis readouts so reduced bacterial signal is not mistaken for a specific endocytosis effect.

• Cefiderocol Activity in Resistant European Isolates

  2026-09-17

  This European surveillance study directly compared cefiderocol with recent β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa and Acinetobacter spp., including meropenem-resistant isolates. Its large, phenotype-stratified design found consistently high cefiderocol susceptibility and linked resistance subsets to acquired β-lactamases and mutations in iron-uptake pathways, while also clarifying the limits of in vitro comparisons.

• Polybrene Workflows for Gene Delivery and Metabolic Studies

  2026-09-17

  Polybrene improves viral attachment and can strengthen lipid-mediated DNA delivery, making it useful for difficult-to-transfect cells. This guide connects those delivery workflows with experimental tests of the TCAIM–OGDH mitochondrial pathway while emphasizing controls, cytotoxicity checks, and practical optimization.

7961 records 1/531 page Next 12345 下5页 Last page